Emergent Biosolutions Inc

Healthcare · Drug Manufacturers - Specialty & Generic

6.80$ +3.2% vs. previous close Closing price · As of: Sep 22, 2026

Statements

Income Statement

Emergent Biosolutions Inc (EBS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 234 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement EBS
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	143	152	117	101	149	194	118	220	174	271	191	243	312	336	193	395	385	583	343	398	329	723	308	240	240	331	164	338	271	277	300	255	294	195	222	141	231	149	156	234	770
Cost of Revenue	67	65	66	60	66	84	83	110	106	162	138	165	161	133	119	178	204	227	151	277	266	296	202	221	189	167	189	215	178	107	160	320	130	58	106	83	102	102	89	97	390
Gross Profit	76	86	50	41	83	110	34	110	67	108	53	79	150	203	74	217	181	356	192	121	63	428	106	19	51	163	-24	123	92	169	141	-66	164	137	117	58	129	47	68	137	381
Research & Development	27	27	20	26	23	29	29	25	37	52	46	64	53	63	43	48	84	60	53	49	50	83	46	53	42	58	41	26	15	29	15	33	14	9.1	15	13	14	12	11	9.2	45
Selling, General & Administrative	41	125	35	32	35	102	40	40	42	122	65	71	65	201	70	76	76	146	80	91	82	94	85	81	80	94	101	91	86	90	85	86	77	61	52	44	39	51	47	45	181
Total Operating Expenses	41	35	36	32	35	56	44	43	46	97	80	86	80	126	85	91	120	98	97	106	98	150	99	95	96	229	123	416	335	213	101	138	100	146	68	57	52	63	57	262	435
Operating Income	35	51	15	8.5	48	53	-9.5	67	21	11	-27	-7.0	71	78	-12	126	61	258	95	15	-35	277	6.4	-76	-45	-65	-148	-293	-242	-44	40	-204	65	-9.5	49	0.5	77	-17	11	-125	-54
Interest Expense	2.0	2.5	1.9	1.8	2.0	0.9	0.2	1.0	0.6	8.0	9.6	9.5	10	9.1	8.6	6.4	7.6	8.7	8.5	8.6	8.4	9.0	8.2	7.8	8.5	13	18	29	20	22	24	24	8.3	15	15	15	15	15	11	10	51
Pre-Tax Income	34	49	14	6.7	46	52	-9.4	66	22	3.5	-38	-15	59	72	-21	121	55	253	85	7.2	-46	268	-3.8	-87	-67	-71	-161	-250	-266	-55	12	-270	142	-28	93	-17	58	-51	13	-166	-146
Income Tax Expense	13	17	3.2	2.1	13	18	-4.5	16	0.6	7.0	-12	-5.6	16	25	-8.8	28	16	67	16	2.6	-13	78	-0.1	-33	20	17	26	11	-2.5	-5.0	3.1	13	28	3.7	25	-4.8	6.4	3.9	6.6	14	31
Net Income	21	37	10	4.6	34	34	-4.9	50	21	-3.5	-26	-9.5	43	47	-13	93	40	185	70	4.6	-33	189	-3.7	-54	-87	-88	-186	-261	-263	-50	9.0	-283	115	-31	68	-12	51	-55	6.8	-180	-177
EBITDA	50	67	25	19	58	72	2.8	79	34	44	-1.2	21	98	109	16	154	118	286	124	48	-2.5	347	36	-44	-1.2	-65	-104	48	23	-14	63	-132	98	21	133	22	97	-13	49	-156	-24

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings